1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

  • December 2015
  • 42 pages
  • ID: 3524428
In this report:
The five-year diagnosed prevalent cases of brain cancer are also expected to increase from ##,## cases in 2014 to ##,## cases in 2024, at an AGR of ##.##%.
In the seven major markets (##MM) (US, France, Germany, Italy, Spain, UK, and Japan), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from ##,## cases in 2014 to ##,## cases in 2024, at an Annual Growth Rate (AGR) of ##.##%.

Summary

Table of Contents

EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024

Brief

Primary brain cancer is defined as a malignant neoplasm that originates in the central nervous system, which consists of the brain and spinal cord, containing the brain stem (NCI, 2015). The American Brain Tumor Association reports that there are over 120 distinct types of malignant and benign brain tumors, (ABTA, 2014). The type and severity of a brain tumor is defined by the cells from which the tumor originated, as well as by the proliferative potential of the abnormal growth, and only those tumors that are malignant are designated as cancer (NCI, 2015). Primary brain tumors are those that start in the brain and may, in time, migrate elsewhere in the body, while metastatic brain tumors are those that start elsewhere in the body and migrate to the brain or other parts of the CNS.

In the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)), GlobalData epidemiologists forecast that the diagnosed incident cases of brain cancer will increase from 55,084 cases in 2014 to 62,226 cases in 2024, at an Annual Growth Rate of ~1.3 percent. The U.S. will have the more significant number of diagnosed incident cases of brain cancer among the 7MM throughout the forecast period. The 5-year diagnosed prevalent cases of brain cancer are also anticipated to increase from 84,704 cases in 2014 to 89,984 cases in 2024, at an AGR of ~0.6 percent. The U.S. will have the more important number of 5-year diagnosed prevalent cases of brain cancer in 2014 and 2024, at 42,104 cases and 46,401 cases, respectively.

This business report offers an overview of the risk factors, comorbidities, and the overall and historical trends for brain cancer in the 7MM. It includes a 10-year epidemiological forecast for the diagnosed incident cases and the 5-year diagnosed prevalent cases of brain cancer, each broken down by sex and age. On top of, it includes a forecast for the diagnosed incident cases of brain cancer, split by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma). This forecast for brain cancer includes only primary malignant brain tumors originating in the CNS (ICD-10 codes C70-C72).

Overview

- The brain cancer EpiCast Report offers an overview of the risk factors, comorbidities, and the overall and historical trends for brain cancer in the seven main markets (7MM) (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). This industry report includes a 10-year epidemiological forecast for the diagnosed incident cases and the 5-year diagnosed prevalent cases of brain cancer, each divided by sex and age. On top of, it includes a forecast for the diagnosed incident cases of brain cancer, broken down by type (glioblastoma, meningioma, ependymoma, oligodendroglioma, and CNS lymphoma).

- The brain cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The brain cancer EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall brain cancer market.

- Quantify patient populations in the overall brain cancer market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for brain cancer therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

Clinical Research in Glioblastoma Multiforme (GBM) in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017" provides an overview ...

Adult Malignant Glioma Global Clinical Trials Review, H1, 2017

Clinical Research in Adult Malignant Glioma in H1, 2017

  • $ 2500
  • Industry report
  • March 2017
  • by GlobalData

Adult Malignant Glioma Global Clinical Trials Review, H1, 2017SummaryGlobalData’s clinical trial report, “Adult Malignant Glioma Global Clinical Trials Review, H1, 2017" provides an overview of Adult ...

Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017

Clinical Research in Anaplastic Oligoastrocytoma in H1, 2017

  • $ 2500
  • Industry report
  • March 2017
  • by GlobalData

Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017SummaryGlobalData’s clinical trial report, “Anaplastic Oligoastrocytoma Global Clinical Trials Review, H1, 2017" provides an overview ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • December 2017
    113 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer Statistics in the UK

  • November 2017
    19 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Biological Therapy Industry in the US - Forecast

  • October 2017
    12 pages
  • Breast Cancer  

  • United States  

View report >

Related Market Segments :

Brain Cancer

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.